Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00090766
Registration number
NCT00090766
Ethics application status
Date submitted
3/09/2004
Date registered
6/09/2004
Date last updated
31/10/2016
Titles & IDs
Public title
A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Query!
Scientific title
Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients
Query!
Secondary ID [1]
0
0
WV16726
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cytomegalovirus Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - valganciclovir [Valcyte]
Experimental: Valganciclovir Age Group <= 2 Years - Eligible participants aged <= 2 years received valganciclovir up to maximum of 900 milligrams (mg) once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * body surface area (BSA) * creatinine clearance (CrCLS).
Experimental: Valganciclovir Age Group >2 to <12 Years - Eligible participants aged >2 to <12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
Experimental: Valganciclovir Age Group >= 12 Years - Eligible participants aged >= 12 years received valganciclovir up to maximum of 900 mg once daily oral dose (solution or tablets) from the time of kidney transplantation for up to 100 days post-transplant. Dose = 7 * BSA * CrCLS.
Treatment: Drugs: valganciclovir [Valcyte]
po daily (dose based on body surface area and CrCL)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Area Under the Concentration-Time Curve From 0 to 24 Hours of Valganciclovir
Query!
Assessment method [1]
0
0
Area Under the Plasma Concentration-Time Curve (AUC) is a measure of the plasma concentration of the drug over time. The AUC 0-24 hours is area under the plasma concentration-time curve from time zero through 24 hours after dosing. A compartmental model was used to measure the plasma concentrations of valganciclovir. One participant was not analyzed for this outcome measure as the participant underwent both a kidney and liver transplant.
Query!
Timepoint [1]
0
0
Pre-dose; 1-3, 3-7, 7-12 hours post dose on any day between Day 7 to Day 14; Week 6, Week 10, and Week 14
Query!
Primary outcome [2]
0
0
Number of Participants With Adverse Events Leading to Dose Interruption or Modification
Query!
Assessment method [2]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation in participant administered a pharmaceutical product, which did not necessarily have to have a causal relationship with this treatment. The number of participants with AEs leading to dose interruptions or modifications are reported.
Query!
Timepoint [2]
0
0
Up to Week 26
Query!
Primary outcome [3]
0
0
Number of Participants With Opportunistic Infections
Query!
Assessment method [3]
0
0
Opportunistic infections included oral candidiasis, candidiasis, herpes simplex, cytomegalovirus antigen positive, cytomegalovirus test positive. The number of participants with opportunistic infections are reported.
Query!
Timepoint [3]
0
0
Up to Week 26
Query!
Primary outcome [4]
0
0
Number of Participants With Any Adverse Events and Any Serious Adverse Events
Query!
Assessment method [4]
0
0
An AE was defined as any untoward medical occurrence in a clinical investigation in participant administered a pharmaceutical product, which did not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is any experience or a significant hazard, that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing one, results in persistent or significant disability, is a congenital anomaly, is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Query!
Timepoint [4]
0
0
Up to Week 26
Query!
Primary outcome [5]
0
0
Number of Participants With Adverse Events Leading to Discontinuation of the Study Drug
Query!
Assessment method [5]
0
0
An AE was defined as any untoward medical occurrence in a clinical investigation in participant administered a pharmaceutical product, which did not necessarily have to have a causal relationship with this treatment. The number of participants with AEs leading to discontinuation of the study drug is reported.
Query!
Timepoint [5]
0
0
Up to Week 26
Query!
Primary outcome [6]
0
0
Number of Participants With 3 Grade Shift From Baseline of Adverse Events in Hematology and Serum Chemistry
Query!
Assessment method [6]
0
0
The number of participants experiencing a 3 grade shift (example from Grade 0 to Grade 3) from baseline (BL) in hematology and serum chemistry laboratory parameters are reported. The data was analyzed for overall study only.
Query!
Timepoint [6]
0
0
Up to Week 26
Query!
Primary outcome [7]
0
0
Number of Participants With 4 Grade Shift From Baseline of Adverse Events in Hematology and Serum Chemistry
Query!
Assessment method [7]
0
0
The number of participants experiencing a 4 grade shift (example from Grade 0 to Grade 4) from BL in hematology and serum chemistry laboratory parameters are reported. The data was analyzed for overall study only.
Query!
Timepoint [7]
0
0
Up to Week 26
Query!
Secondary outcome [1]
0
0
Number of Participants With Cytomegalovirus Disease Over Time
Query!
Assessment method [1]
0
0
Cytomegalovirus (CMV) disease is defined as syndrome or tissue invasive disease in which CMV virus was identified in blood, urine, biopsy or other suitable specimen, which could be in conjunction with one or more of the following events: a) CMV syndrome was defined as virus present in blood or other suitable specimen, plus fever, and any of the following: leukopenia, atypical lymphocytosis, thrombopenia or elevated hepatic transaminases (for non-liver recipients). b) The diagnosis of organ specific tissue invasive CMV disease was evidence of CMV in the tissue (CMV inclusion bodies or in situ detection of CMV antigen or DNA), plus signs/symptoms of organ dysfunction.
Query!
Timepoint [1]
0
0
Up to Week 26
Query!
Secondary outcome [2]
0
0
Number of Participants With Treatment Failures
Query!
Assessment method [2]
0
0
Treatment failure was defined as either the development of CMV (viremia, antigenemia or test positive) requiring treatment up to day 100 post-transplant (i.e, while undergoing prophylaxis with valganciclovir up to day 100) or discontinuation of study medication due to lack of efficacy or to toxicity.
Query!
Timepoint [2]
0
0
Up to Week 26
Query!
Secondary outcome [3]
0
0
Number of Participants Who Experienced Graft Loss
Query!
Assessment method [3]
0
0
Graft loss was defined as impairment of organ function to such a degree that the participant died or underwent re-transplantation.
Query!
Timepoint [3]
0
0
Up to Week 26
Query!
Secondary outcome [4]
0
0
Mean Maximum Plasma Concentration of Valganciclovir Over Time
Query!
Assessment method [4]
0
0
Maximum Plasma Concentration (Cmax) is defined as the maximum observed plasma concentration of Valganciclovir. Participants with kidney, liver and heart transplant were analyzed. One participant was not analyzed for this outcome measure as the participant underwent both a kidney and liver transplant.
Query!
Timepoint [4]
0
0
Pre-dose; 1-3, 3-7, 7-12 hours post dose on any day between Day (D) 7 to D 14; and at Week (W) 6, W 10, and W 14
Query!
Secondary outcome [5]
0
0
Mean Elimination Half-Life of Valganciclovir Over Time
Query!
Assessment method [5]
0
0
The Elimination Half-Life Period is defined as the time measured for the plasma concentration to decrease by half to its original concentration. One participant was not analyzed for this outcome measure as the participant underwent both a kidney and liver transplant. Here n represents number of participant with specific transplant i.e., kidney, liver, and heart.
Query!
Timepoint [5]
0
0
Pre-dose; 1-3, 3-7, 7-12 hours post dose on any day between Day 7 to Day 14; Week 6, Week 10, and Week 14
Query!
Secondary outcome [6]
0
0
Number of Participants Who Experienced Episodes of Rejection Over Time
Query!
Assessment method [6]
0
0
Participants with biopsy proven active rejection are reported.
Query!
Timepoint [6]
0
0
Up to Week 26
Query!
Eligibility
Key inclusion criteria
- patients between 3 months and 16 years of age;
- first solid organ transplant (eg, kidney, liver, heart);
- able to tolerate oral medication;
- females of childbearing potential must agree to utilize an effective method of
contraception throughout the study and for 90 days following discontinuation of study
drug;
- patients at risk of developing CMV disease (all transplant recipients other than those
who are D-R- for CMV).
Query!
Minimum age
3
Months
Query!
Query!
Maximum age
16
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- patients who have previously participated in this study;
- patients who are participating in another clinical trial (except with the approval of
the Sponsor);
- severe, uncontrolled diarrhea (more than 5 watery stools per day);
- pregnant or lactating females.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2/Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
63
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Indiana
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Michigan
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Missouri
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Utah
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Alberta
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Manitoba
Query!
Country [9]
0
0
France
Query!
State/province [9]
0
0
Paris
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Berlin
Query!
Country [11]
0
0
Mexico
Query!
State/province [11]
0
0
Guadalajara
Query!
Country [12]
0
0
Mexico
Query!
State/province [12]
0
0
Mexico City
Query!
Country [13]
0
0
Spain
Query!
State/province [13]
0
0
Madrid
Query!
Country [14]
0
0
Spain
Query!
State/province [14]
0
0
Valencia
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will assess the safety and pharmacokinetics of Valcyte syrup in pediatric solid
organ transplant recipients. The anticipated time on study treatment is 3-12 months and the
target sample size is less than 100 individuals.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00090766
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00090766
Download to PDF